Skip to main content
Premium Trial:

Request an Annual Quote

Standard BioTools Authorizes $20M Share Buyback

NEW YORK – Standard BioTools said on Monday that its board of directors has authorized the repurchase of up to $20 million of shares of its common stock in the open market or in negotiated transactions through Dec. 31, 2023.

The life science research tools provider said it expects to make the repurchases from cash on hand, and that it believes this to be an effective use of capital given the company's current valuation and progress to date against recently stated strategic goals.

In August, the company — formerly known as Fluidigm — said that it had begun restructuring to significantly lower its operational expenses through an undisclosed number of layoffs and a reduction in its real estate footprint, including at its South San Francisco, California headquarters.

Earlier this month, Standard BioTools reported that its third quarter revenues dropped 10 percent year over year on lower instrument and COVID-19 testing revenue as its net loss more than doubled year over year. The company finished Q3 with $60.2 million in cash and cash equivalents.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.